Literature DB >> 31468708

Assessing the applicability of 2017 ACC/AHA hypertension guidelines for secondary stroke prevention in the BOSS study.

Xuewei Xie1,2,3,4, Hong-Qiu Gu1,2,3,4, Xianwei Wang1,2,3,4, Pan Chen1,2,3,4, Liping Liu1,2,3,4, Zixiao Li1,2,3,4, Xia Meng1,2,3,4, Yilong Wang1,2,3,4, Yongjun Wang1,2,3,4.   

Abstract

Using data from the Blood Pressure and Clinical Outcome in TIA or Ischemic Stroke (BOSS) study, we aim to test the applicability and feasibility of stroke secondary prevention recommendations from the 2017 American College of Cardiology/American Heart Association guideline. Patients were categorized based on their blood pressure (BP) status at 3 months. The nonhypertension group was defined as those without a diagnosis of hypertension. The other patients were further divided into three subgroups according to office BP measured at 3-month visit (BP <130/80, 130-139/80-89, and ≥140/90 mm Hg). The primary outcome was any stroke within one year. The associations between BP status and 1-year prognosis (recurrent stroke, recurrent stroke/TIA, and poor functional outcome [modified Rankin scale score 3-6]) were estimated. Among 2341 IS/TIA patients, additional 1056 patients were classified as uncontrolled hypertension at the 90-day visit according to the new guidelines. Adjusted hazard/odds ratios (95% confidence intervals [CI]) for recurrent stroke in BP <130/80, 130-139/80-89, and ≥140/90 compared with nonhypertension group were 2.42 (95% CI: 0.87-6.76), and 4.30 (95% CI: 1.73-10.70), respectively. The prevalence of hypertension and uncontrolled BP among BOSS study population was substantially higher based on the new guidelines. BP of 130-139/80-89 did not show the worsened clinical outcomes compared with people without hypertension. Our study adds to the growing uncertainty about secondary prevention BP goal for IS/TIA patients. ©2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  blood pressure; guidelines; ischemic stroke; secondary prevention; transient ischemic attack

Mesh:

Substances:

Year:  2019        PMID: 31468708      PMCID: PMC8030308          DOI: 10.1111/jch.13653

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  27 in total

Review 1.  Lowering of blood pressure for recurrent stroke prevention.

Authors:  Andrea D Boan; Daniel T Lackland; Bruce Ovbiagele
Journal:  Stroke       Date:  2014-07-01       Impact factor: 7.914

2.  Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial.

Authors:  Hisatomi Arima; John Chalmers; Mark Woodward; Craig Anderson; Anthony Rodgers; Stephen Davis; Stephen Macmahon; Bruce Neal
Journal:  J Hypertens       Date:  2006-06       Impact factor: 4.844

3.  Measurements of acute cerebral infarction: a clinical examination scale.

Authors:  T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg
Journal:  Stroke       Date:  1989-07       Impact factor: 7.914

4.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

5.  Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.

Authors:  Walter N Kernan; Bruce Ovbiagele; Henry R Black; Dawn M Bravata; Marc I Chimowitz; Michael D Ezekowitz; Margaret C Fang; Marc Fisher; Karen L Furie; Donald V Heck; S Claiborne Clay Johnston; Scott E Kasner; Steven J Kittner; Pamela H Mitchell; Michael W Rich; DeJuran Richardson; Lee H Schwamm; John A Wilson
Journal:  Stroke       Date:  2014-05-01       Impact factor: 7.914

6.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

Review 7.  Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature.

Authors:  Lisheng Liu; Zengwu Wang; Lansheng Gong; Yuqing Zhang; Lutgarde Thijs; Jan A Staessen; Jiguang Wang
Journal:  Hypertens Res       Date:  2009-10-02       Impact factor: 3.872

8.  Assessing the applicability of 2017 ACC/AHA hypertension guidelines for secondary stroke prevention in the BOSS study.

Authors:  Xuewei Xie; Hong-Qiu Gu; Xianwei Wang; Pan Chen; Liping Liu; Zixiao Li; Xia Meng; Yilong Wang; Yongjun Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-29       Impact factor: 3.738

9.  Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis.

Authors:  Shaheen E Lakhan; Michael T Sapko
Journal:  Int Arch Med       Date:  2009-10-20

10.  The J-curve Association between Systolic Blood Pressure and Clinical Outcomes in Ischemic Stroke or TIA: The BOSS Study.

Authors:  Xuewei Xie; Jie Xu; Hongqiu Gu; Yongli Tao; Pan Chen; Yilong Wang; Yongjun Wang
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more
  1 in total

1.  Assessing the applicability of 2017 ACC/AHA hypertension guidelines for secondary stroke prevention in the BOSS study.

Authors:  Xuewei Xie; Hong-Qiu Gu; Xianwei Wang; Pan Chen; Liping Liu; Zixiao Li; Xia Meng; Yilong Wang; Yongjun Wang
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-08-29       Impact factor: 3.738

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.